Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC699 in ER+/HER2- advanced breast cancer
NCT05654532Phase 1Active, not recruiting
- Sponsor
- Accutar Biotechnology, Inc.
- Start
- Dec 2022
- Primary completion
- Mar 2026
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AC699 in breast cancer, sponsored by Accutar Biotechnology, Inc. Primary endpoints: Dose Limiting Toxicities at 28 days and Treatment-Emergent Adverse Events at 18 months. Started Dec 2022; status: active, not recruiting.
02
Drugs
AC699
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05654532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05654532.